Vol 2, No 1 (2011)
Review paper
Published online: 2011-03-24
Treatment of patients with Philadelphia positive acute lymphoblastic leukemia
Hematologia 2011;2(1):33-42.
Abstract
Translocation (9;22)(q34:q11.2), called Philadelphia chromosome (Ph), is the most frequent
cytogenetic aberration among adults with acute lymphoblastic leukemia (ALL). Before the era
of tyrosine kinase inhibitors (TKI), ALL Ph+ was associated with particularly poor prognosis.
Introduction of imatinib (IM) in combination with induction-consolidation chemotherapy
increased complete remission rate to over 90% and allowed application of allogeneic hematopoietic
stem cell transplantation to greater proportion of patients. First reports on long term
results indicate that 5-year probability of the overall survival is now approximately 50%.
Further improvement requires prospective clinical trials aimed to optimize the protocols of IM
administration and evaluate potential role of 2nd generation TKI in the up-front therapy of
adults with ALL Ph+.
Hematologia 2011; 2, 1: 3341
Hematologia 2011; 2, 1: 3341
Keywords: acute lymphoblastic leukemiaPhiladelphia chromosomeimatinibtyrosine kinase inhibitorstherapytransplantation